Inside informationEnglish
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 22/10/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 114317_20251022